• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over

firstwordpharmaJune 24, 2021

Tag: AstraZeneca , COVID-19 , Vaccine

According to sources, Japan is considering approving the use of AstraZeneca's COVID-19 vaccine for people aged 18 or over, as reported Kyodo News+ on Wednesday.

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over

The Ministry of Health, Labor and Welfare granted fast-track approval for the vaccine in May and is already planning to approve it for people aged 60 or older.

An expert panel of the health ministry will consider the eligible age range for the vaccine on June 30.

Previous:Orion Biotechnology Secures $11.5M Series A Financing

Next:Arcus says early data for anti-TIGIT domvanalimab combos look good, but mum on details

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Meningococcal Polysaccharide Vaccine Group ACYW135

Meningococcal Polysaccharide Vaccine Group ACYW135
Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard
flu vaccine for 2023-2024 northern hemisphere influenza season

flu vaccine for 2023-2024 northern hemisphere influenza season
2023-2024 Recommended composition flu vaccine

2023-2024 Recommended composition flu vaccine
*trivalent flu vaccine

*trivalent flu vaccine
Hualan Influenza Vaccine (Split virion)

Hualan Influenza Vaccine (Split virion)
High-dose trivalent influenza vaccine

High-dose trivalent influenza vaccine
Hualan Influenza Vaccine

Hualan Influenza Vaccine
Haemophilus Influenza Type B Conjugate Vaccine

Haemophilus Influenza Type B Conjugate Vaccine
Pet Vaccine Series

Pet Vaccine Series

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service